Search Contract Opportunities

Drug Development Support for the Cancer Therapy Evaluation Program   4

ID: 75N91021R00043 • Type: Solicitation
Opportunity Assistant

Hello! Please let me know your questions about this opportunity. I will answer based on the available opportunity documents.

Please sign-in to link federal registration and award history to assistant. Sign in to upload a capability statement or catalogue for your company

Some suggestions:
Please summarize the work to be completed under this opportunity
Do the documents mention an incumbent contractor?
I'd like to anonymously submit a question to the procurement officer(s)

Description

Posted: Nov. 19, 2021, 4:25 p.m. EST

Title: Drug Development Support for the Cancer Therapy Evaluation Program (CTEP)

See the attached solicitation/RFP for more information.

The deadline for receipt of proposals is extended to 2pm ET on November 30, 2021.

See attached Amendment 00002 for details.

Posted: Oct. 29, 2021, 2:51 p.m. EDT
Posted: Oct. 15, 2021, 3:44 p.m. EDT
Background
The solicitation is for Drug Development Support for the Cancer Therapy Evaluation Program (CTEP). The document provides detailed instructions for offerors to follow in preparing their proposals, including the technical evaluation criteria and page limitations. It emphasizes the importance of being complete yet succinct in the proposal and limiting the total number of pages to 150. The solicitation also outlines the formatting and layout guidelines for the technical and business proposals.

Work Details
The work details include a comprehensive breakdown of the technical proposal requirements, such as the proposal title page, mandatory qualification criteria, technical discussions, staffing plan, technical approach, corporate experience, facilities and equipment. It also specifies that the contractor must perform Phase-in transition from an incumbent Contract/Contractor within the first 90 days of the effective date of the contract.

Period of Performance
The geographic location(s) where the contract will be performed is not explicitly provided in the given text.

Place of Performance
The geographic location(s) where the contract will be performed is not explicitly provided in the given text.

Overview

Agency
National Institutes of Health (NIH) [HHS]
Response Deadline
Nov. 30, 2021, 2:00 p.m. EST (original: Nov. 16, 2021, 1:00 p.m. EST) Past Due
Posted
Oct. 15, 2021, 3:44 p.m. EDT (updated: Nov. 19, 2021, 4:25 p.m. EST)
Set Aside
None
NAICS
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC
AN13 - Health R&D Services; Health Care Services; Experimental Development
Place of Performance
United States
Source
SAM
Links
NIH eCPS
Current SBA Size Standard
1000 Employees
Pricing
Likely Fixed Price
Est. Level of Competition
Average
On 10/15/21 National Institutes of Health issued Solicitation 75N91021R00043 for Drug Development Support for the Cancer Therapy Evaluation Program due 11/30/21. The opportunity was issued full & open with NAICS 541715 and PSC AN13.
Primary Contact
Name
DeChanta Vaughan, Contract Specialist   Profile
Email
dechanta.vaughan@nih.gov
Phone
(240) 276-5536

Secondary Contact

Name
Pooja Rathore   Profile
Email
pooja.rathore@nih.gov
Phone
(240) 276-7325

Documents

Posted documents for Solicitation 75N91021R00043

Question & Answer

The AI Q&A Assistant has moved to the bottom right of the page

Opportunity Lifecycle

Procurement notices related to Solicitation 75N91021R00043

Award Notifications

Agency published notification of awards for Solicitation 75N91021R00043

Contract Awards

Prime contracts awarded through Solicitation 75N91021R00043

Incumbent or Similar Awards

Potential Bidders and Partners

Awardees that have won contracts similar to Solicitation 75N91021R00043

Similar Active Opportunities

Open contract opportunities similar to Solicitation 75N91021R00043

Additional Details

Source Agency Hierarchy
HEALTH AND HUMAN SERVICES, DEPARTMENT OF > NATIONAL INSTITUTES OF HEALTH > NIH NCI
FPDS Organization Code
7529-00316
Source Organization Code
100188082
Last Updated
Nov. 19, 2021
Last Updated By
dechanta.vaughan@nih.gov
Archive Date
June 30, 2022